MONETTE LALIMAR: Open Payments
NPI 1720147440 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,075 in 146 payments from 25 companies in 2025. Trend: 2023 $4,826 · 2024 $4,121 · 2025 $3,075
Food & beverage: $3,018Education: $57
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $408 |
| UCB, Inc. | 15 | $367 |
| Novartis Pharmaceuticals Corporation | 14 | $325 |
| Merz Pharmaceuticals, LLC | 10 | $309 |
| Teva Pharmaceuticals USA, Inc. | 20 | $212 |
| Amgen Inc. | 4 | $179 |
| Eisai Inc. | 9 | $159 |
| Biogen, Inc. | 7 | $157 |
| Lundbeck LLC | 8 | $153 |
| GENZYME CORPORATION | 2 | $135 |
Products named: KESIMPTA, Xeomin, QULIPTA, AUSTEDO XR, Leqembi, Fintepla, VYEPTI, UPLIZNA.
Industry payments across CA — which companies pay providers there.
